Napredna pretraga

Pregled bibliografske jedinice broj: 277113

Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats

Boban Blagaić, Alenka; Blagaić, Vladimir; Mirt, Mirela; Jelovac, Nikola; Dodig, Goran; Ručman, Rudolf; Petek, Marijan; Turković, Branko; Anić, Tomislav; Dubovećak, Miroslav et al.
Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats // European journal of pharmacology, 512 (2005), 2-3; 173-179 doi:10.1016/j.ejphar.2005.02.033 (međunarodna recenzija, članak, znanstveni)

Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats

Boban Blagaić, Alenka ; Blagaić, Vladimir ; Mirt, Mirela ; Jelovac, Nikola ; Dodig, Goran ; Ručman, Rudolf ; Petek, Marijan ; Turković, Branko ; Anić, Tomislav ; Dubovećak, Miroslav ; Starešinić, Mario ; Seiwerth, Sven ; Sikirić, Predrag

European journal of pharmacology (0014-2999) 512 (2005), 2-3; 173-179

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Serotonin syndrome ; pargyline ; L-tryptophan ; hyperthermia ; hypothermia ; hind limbs abduction ; pentadecapeptide BPC 157 ; rats

Serotonin syndrome commonly follows irreversible monoamine oxidase (MAO)-inhibition and subsequent serotonin (5-HT) substrate (in rats with fore paw treading, hind limbs abduction, wet dog shake, hypothermia followed by hyperthermia). A stable gastric pentadecapeptide BPC 157 with very safe profile (inflammatory bowel disease clinical phase II, PL-10, PLD-116, PL-14736, Pliva) reduced the duration of immobility to a greater extent than imipramine, and, given peripherally, has region specific influence on brain 5-HT synthesis (alpha-[14C]methyl-L-tryptophan autoradiographic measurements) in rats, different from any other serotonergic drug. Thereby, we investigate this peptide (10 microg, 10 ng, 10 pg/kg i.p.) in (i) full serotonin syndrome in rat combining pargyline (irreversible MAO-inhibition ; 75 mg/kg i.p.) and subsequent L-tryptophan (5-HT precursor ; 100 mg/kg i.p. ; BPC 157 as a co-treatment), or (ii, iii) using pargyline or L-tryptophan given separately, as a serotonin-substrate with (ii) pargyline (BPC 157 as a 15-min posttreatment) or as a potential serotonin syndrome inductor with (iii) L-tryptophan (BPC 157 as a 15 min-pretreatment). In all experiments, gastric pentadecapeptide BPC 157 contrasts with serotonin-syndrome either (i) presentation (i.e., particularly counteracted) or (ii) initiation (i.e., neither a serotonin substrate (counteraction of pargyline), nor an inductor for serotonin syndrome (no influence on L-tryptophan challenge)). Indicatively, severe serotonin syndrome in pargyline + L-tryptophan rats is considerably inhibited even by lower pentadecapeptide BPC 157 doses regimens (particularly disturbances such as hyperthermia and wet dog shake thought to be related to stimulation of 5-HT2A receptors), while the highest pentadecapeptide dose counteracts mild disturbances present in pargyline rats (mild hypothermia, feeble hind limbs abduction). Thereby, in severe serotonin syndrome, gastric pentadecapeptide BPC 157 (alone, no behavioral or temperature effect) has a beneficial activity, which is likely, particular, and mostly related to a rather specific counteraction of 5-HT2A receptors phenomena.

Izvorni jezik

Znanstvena područja
Temeljne medicinske znanosti

Časopis indeksira:

  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus

Uključenost u ostale bibliografske baze podataka:

  • BIOSIS Previews (Biological Abstracts)
  • CA Search (Chemical Abstracts)
  • EMBASE (Excerpta Medica)